


U.S. Meibomian Gland Dysfunction Market Size and Share Worth US\$ 8,292.0 Million | CAGR of 15.4% By 2027 | Pfizer Inc.,

SEATTLE , WASHINGTON, UNITED STATES, January 25, 2022 /EINPresswire.com/ -- [U.S. Meibomian Gland Dysfunction Market](#) Research focuses on the crucial trends prevailing in the Global U.S. Meibomian Gland Dysfunction Industry sector. The being Assiduity script has been studied and unborn protrusions with respect to the sector have also been delved. Request study report comprises evaluation of multitudinous influential factors including assiduity overview in terms of major and present situation, crucial manufacturers, product/ service operation and types, crucial regions and commerce, cast estimation for global request share, profit and CAGR.



0.0. 0000000000 000000 00000000000000 0000000 00 00000000000 00 000 000000000000 00 00000000000 0000000 00000000000000 0000000000 00 000000000000 00 000 00000000

0000000000:

Meibomian Gland Dysfunction is a common condition in which the eyelids fail to produce the oil layer necessary for maintaining eye moisture. The oil produced by these glands is called meibum and it forms three layers in the tear film. Meibomian gland dysfunction prevents the water layer on the surface of the eye from evaporating. Meibomian gland dysfunction is caused by a variety of factors, however, it is most common in women over 50. As a result, meibomian gland function decreases with age. Fortunately, meibomian gland dysfunction can be treated with proper eye care.

00 000 0000000 00000000 00000 00000000 000000000 00000000 0000000000 @ <https://www.coherentmarketinsights.com/insight/request-sample/4186>

□□□□□□ □□□□□□□□:

Rise in the cases of meibomian gland dysfunction syndrome is expected to boost growth of the U.S. meibomian gland dysfunction market during the forecast period. The meibomian gland dysfunction syndrome causes dry eyes, and around 50 to 70% old age population across the globe experience dry eyes out of which, around 70% are dry eye have meibomian gland dysfunction. For instance, according to the National Center for Biotechnology Information in 2017, in a research studying prevalence on meibomian gland dysfunction syndrome, 59% of male cohort of age 63 year out of 91%, was suffering from the meibomian gland dysfunction syndrome.

However, factors such as potential side effects of medication used in the treatment of the disease are expected to hamper growth of the U.S. meibomian gland dysfunction market during the forecast period.

□□□□□□ □□ □□□□□□-□□:

The outbreak of COVID-19 in China led to spread of the virus across 100 countries causing nationwide lockdowns. The stringent lockdown regulations and movement restrictions across countries affected economy of several countries including the U.S., as the manufacturing, distribution activities were disrupted due to decline in demand of products across various industries. Thus, the U.S. meibomian gland dysfunction market witnessed a negative impact of COVID-19 outbreak.

□□□ □□□ □□□ □□□ □□□□ □□% □□□□□□□□□

□□□□□□□□ □□□□ □□□□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□□□□□□□□□□ @ <https://www.coherentmarketinsights.com/promo/buynow/4186>

□□□ □□□□□□□□□□:

- The U.S. meibomian gland dysfunction market is expected to grow, with a CAGR of 15.4% over the forecast period, due to rising excessive use of mobile screens and computers. For instance, a survey for 'computer and internet use in the U.S.', reported by the U.S. Census Bureau in August 2018, out of total number of households, 71% of people were smartphone users, 77 % were tablet users, and 71% people were desktop or laptop users in the U.S.
- Major players in the market are focused on the launch of new products for the treatment of meibomian gland dysfunction syndrome in the region. For instance, in December 2021, The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Sight Sciences, Inc., an eyecare technology company for The TearCare System for the treatment of meibomian gland dysfunction.

• Key players functioning in the U.S. meibomian gland dysfunction syndrome market include Akorn, Inc., Pfizer, Inc., RegeneRx, AbbVie Inc., Sentiss Pharma Pvt. Ltd., Johnson and Johnson Vision Care Inc., OASIS Medical, Bausch Health Companies Inc., I-MED Pharma Inc., Novartis AG, and Santen Pharmaceutical Co., Ltd.

☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ @

<https://www.coherentmarketinsights.com/insight/request-pdf/4186>

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah

Coherent Market Insights Pvt. Ltd.

+1 206-701-6702

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561472667>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.